Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Phenylephrine · Phenylephrine Hci, Phenylephrine Hydrochloride

Small molecule · Agonist of alpha-1 adrenergic receptor (ADRA1A) · developed by Hikma

Approved FDA, Dec 2012
3 Registered trials

What is Phenylephrine?

Phenylephrine is an alpha-1 adrenergic receptor agonist that causes vasoconstriction and increases blood pressure.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Phenylephrine Hci, Phenylephrine Hydrochloride, Vazculep
Drug type
Small molecule
Targets
alpha-1 adrenergic receptor (ADRA1A)
Mechanism
Agonist of alpha-1 adrenergic receptor (ADRA1A)
Pathways
vasoconstriction
Therapy area
Ophthalmology
Developer
Hikma
In trials of
BLRX, OMER
FDA status
Approved as Phenylephrine Hci, Phenylephrine Hydrochloride, Vazculep (December 20, 2012), NDA203826 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Dec 26, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04829799 Phase 4 Pain Reduction Withdrawn OMER
NCT02132312 Phase 3 Unilateral Cataract Extraction Completed OMER
NCT00374881 Phase 1/2 Acute Pain Completed BLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute PainCongenital CataractPain ReductionUnilateral Cataract Extraction

Other drugs acting on ADRA1A

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.